Burning feet that make sleep impossible. An electric current nobody else can feel running down your leg. Skin so sensitive that a bedsheet becomes unbearable. These aren’t dramatic descriptions for effect. They’re how patients with neuropathic pain describe Tuesday.
Most of them arrive at a specialist having already tried two or three medications that helped a little, then stopped, or helped not at all. The dorsal root ganglion has become one of the more compelling treatment targets in this space, precisely because it represents a mechanistic departure from everything that came before it. But before getting there, it helps to understand why the standard approaches keep underperforming in ways that surprise nobody who actually treats this condition regularly.
What exactly keeps failing, and why?
The Drug Problem Is Structural, Not Incidental
Neuropathic pain doesn’t come from damaged tissue broadcasting ongoing injury. It comes from a nervous system that has been altered. Sensitized pathways. Dysfunctional signal processing. A brain and spinal cord that have reorganized around chronic abnormal input and now generate pain as a kind of learned reflex.
Medications designed for other kinds of pain don’t reach this mechanism cleanly. Anti-inflammatories do almost nothing. Opioids produce short-term relief that deteriorates over months, and the longer-term data is genuinely unfavorable.
Anticonvulsants like gabapentin and pregabalin reduce abnormal nerve firing, which helps meaningfully for a portion of patients and produces sedation and cognitive fog for many others without touching the pain. The underlying issue is that neuropathic pain isn’t one thing. A drug calibrated for one mechanism is essentially irrelevant to patients whose pain runs through a different pathway.
Common medications and what limits them:
● Gabapentinoids reduce nerve firing but sedate many patients without adequately reducing pain
● Tricyclic antidepressants modulate descending inhibition but carry cardiovascular and anticholinergic risks
● SNRIs like duloxetine perform consistently for diabetic neuropathy and unpredictably for almost everything else
● Opioids provide initial relief that typically erodes and introduces dependency and tolerance problems
● Topical agents address localized surface pain but cannot reach deeper neural dysfunction driving the condition
When the Approach Has to Change
Interventional pain medicine steps in at the point where medications have demonstrated their ceiling. The first line of interventional treatment is usually nerve blocks. Injecting local anesthetic near a specific nerve structure can interrupt the pain signal at its anatomical source. For patients whose pain sits in a definable territory, this can provide relief that months of medication couldn’t.
Sometimes the relief is temporary but breaks a self-sustaining cycle. Sometimes it’s diagnostic, confirming where the signal originates. Radiofrequency ablation applies heat to disrupt nerve conduction over a longer period. It works reliably for some pain generators, less predictably for the diffuse presentations that characterize much neuropathic pain.
Spinal cord stimulation delivers electrical signals near the spinal cord, interfering with pain transmission before it reaches conscious experience. It has decades of evidence, particularly for failed back surgery syndrome and certain presentations of complex regional pain syndrome. The limitation is anatomical precision.
The spinal cord serves large regions. Pain concentrated in specific territories, the foot, the groin, the knee, often responds incompletely because the stimulation can’t be targeted narrowly enough.
The DRG Difference
Here is what changes with dorsal root ganglion stimulation. The DRG is a cluster of nerve cell bodies positioned just outside the spinal cord at each vertebral level. Every sensory signal from a specific body territory travels through it on the way to the central nervous system. The foot has its DRG. The groin has its DRG. These territories are anatomically discrete in a way that spinal cord targets are not.
Stimulating a specific DRG modulates sensory input from exactly that territory. The precision is genuinely different from anything that operates at the spinal cord level.
The DRG also happens to be a site of pathological activity in neuropathic conditions.
Satellite cells activate. Ion channels upregulate. The ganglion becomes a node of abnormal firing that perpetuates the chronic pain state. Stimulation addresses the problem at this specific location rather than trying to manage it downstream after it has already entered the central processing system.
Conditions where DRG stimulation shows meaningful clinical response:
1. Complex regional pain syndrome affecting the foot, ankle, or knee
2. Groin and pelvic pain following hernia repair or other surgeries with regional nerve involvement
3. Painful diabetic neuropathy in dermatomally defined distributions
4. Post-surgical pain persisting after joint replacement in the lower extremity
5. Focal lower limb neuropathic pain that conventional spinal cord stimulation couldn’t adequately cover
Controlled trials comparing DRG stimulation to conventional spinal cord stimulation for lower limb CRPS showed DRG superiority, particularly for foot pain. The precision advantage translated into clinical outcomes. Two-year follow-up data support durability of response in patients who were well-selected.
Conclusion
The toolkit for neuropathic pain has expanded considerably, but matching the right tool to the right patient requires understanding what each one actually targets. DRG stimulation doesn’t replace pharmacology or conventional stimulation. It addresses a subset of patients whose pain is focal, whose territorial distribution corresponds to specific ganglia, and who haven’t gotten there through everything that came before. That subset is larger than most people realize. And for them, the specificity that DRG targeting provides changes the outcome in ways that adding another medication simply cannot.
FAQs
Is DRG stimulation reversible?
Yes. The system can be adjusted, reprogrammed, or removed. Most patients undergo a trial period first to confirm the response before permanent implantation.
How is it different from regular spinal cord stimulation?
Conventional stimulation targets broad spinal regions. DRG stimulation targets the specific ganglion serving the painful territory, producing far more anatomically focused coverage.
Who actually benefits from this?
Patients with focal neuropathic pain in specific body territories, particularly the lower extremities, who haven’t responded to conservative treatment or conventional stimulation. Selection determines outcome.
How long do results last?
Studies show sustained benefit at two years in well-selected patients. Individual results depend on underlying condition and programming optimization over time.